Narendiran Rajasekaran
Research Subjects
Narendiran Rajasekaran has a total of 128 co-authors. Here are the top co-authors by number of shared publications:
- Austin Dulak
Surface Oncology, Boston, Massachusetts
13 shared publications - Daniel J. Chin
Coherus Oncology 1 , Redwood City, California
13 shared publications - Federico Baruffaldi
Coherus Oncology 1 , Redwood City, California
13 shared publications - James F. Mohan
Coherus Oncology 1 , Redwood City, California
13 shared publications - Jonathan A. Hill
Coherus Oncology 1 , Redwood City, California
13 shared publications - Marisella Panduro
Surface Oncology, Boston, Massachusetts
13 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from CHS-114: An Afucosylated Anti-CCR8 Monoclonal Antibody that Selectively Depletes Intratumoral Treg Cells and Induces Antitumor Immune Responses
Human tumors types used in Figure 1
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from CHS-114: An Afucosylated Anti-CCR8 Monoclonal Antibody that Selectively Depletes Intratumoral Treg Cells and Induces Antitumor Immune Responses
Human tumors types used in Figure 1
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Data from CHS-114: An Afucosylated Anti-CCR8 Monoclonal Antibody that Selectively Depletes Intratumoral Treg Cells and Induces Antitumor Immune Responses
Intratumoral T regulatory cells (Treg) promote an immunosuppressive tumor microenvironment and are frequently associated with a lack of response to immunotherapy. Selective targeting of intratumoral Tregs while sparing broader Tregs and effector T-cell populations is an attractive strategy to enhance antitumor immune responses. C-C motif chemokine receptor 8 (CCR8) is a G protein–coupled receptor that is predominantly upregulated on tumor-resident Tregs in a range of human solid tumors, making it a promising target for their selective depletion. In preclinical studies using mouse tumor models, anti-mouse CCR8 antibody treatment resulted in depletion of CCR8+ intratumoral Tregs, significant antitumor activity, and enhanced survival in combination with anti–PD-1. CHS-114 is a highly selective, afucosylated human anti-CCR8 monoclonal antibody that is being developed as a cancer immunotherapy. CHS-114 selectively binds human CCR8 and potently kills CCR8 expressing cells by inducing antibody-dependent cellular cytotoxicity and antibody-dependent cellular phagocytosis. Ex vivo studies evaluating human dissociated tumor cells demonstrated the selectivity of CHS-114 in depleting intratumoral Tregs while sparing CCR8-negative Tregs and effector T cells. Treatment of tumor-bearing human CCR8 knock-in (huCCR8KI) mice with CHS-114 resulted in significant tumor growth inhibition (62.6%) accompanied by remodeling of the tumor-immune microenvironment and enhanced differentiation of a subset of cytotoxic CD8+ T cells. Based on the promising preclinical data, we are evaluating CHS-114 in clinical trials as an investigational agent for the treatment of solid tumors with and without the anti–PD-1 antibody toripalimab (NCT05635643 and NCT06657144).
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from CHS-114: An Afucosylated Anti-CCR8 Monoclonal Antibody that Selectively Depletes Intratumoral Treg Cells and Induces Antitumor Immune Responses
Intratumoral T regulatory cells (Treg) promote an immunosuppressive tumor microenvironment and are frequently associated with a lack of response to immunotherapy. Selective targeting of intratumoral Tregs while sparing broader Tregs and effector T-cell populations is an attractive strategy to enhance antitumor immune responses. C-C motif chemokine receptor 8 (CCR8) is a G protein–coupled receptor that is predominantly upregulated on tumor-resident Tregs in a range of human solid tumors, making it a promising target for their selective depletion. In preclinical studies using mouse tumor models, anti-mouse CCR8 antibody treatment resulted in depletion of CCR8+ intratumoral Tregs, significant antitumor activity, and enhanced survival in combination with anti–PD-1. CHS-114 is a highly selective, afucosylated human anti-CCR8 monoclonal antibody that is being developed as a cancer immunotherapy. CHS-114 selectively binds human CCR8 and potently kills CCR8 expressing cells by inducing antibody-dependent cellular cytotoxicity and antibody-dependent cellular phagocytosis. Ex vivo studies evaluating human dissociated tumor cells demonstrated the selectivity of CHS-114 in depleting intratumoral Tregs while sparing CCR8-negative Tregs and effector T cells. Treatment of tumor-bearing human CCR8 knock-in (huCCR8KI) mice with CHS-114 resulted in significant tumor growth inhibition (62.6%) accompanied by remodeling of the tumor-immune microenvironment and enhanced differentiation of a subset of cytotoxic CD8+ T cells. Based on the promising preclinical data, we are evaluating CHS-114 in clinical trials as an investigational agent for the treatment of solid tumors with and without the anti–PD-1 antibody toripalimab (NCT05635643 and NCT06657144).
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S8 from CHS-114: An Afucosylated Anti-CCR8 Monoclonal Antibody that Selectively Depletes Intratumoral Treg Cells and Induces Antitumor Immune Responses
Treg gating strategy of CHS-114 clinical samples
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S8 from CHS-114: An Afucosylated Anti-CCR8 Monoclonal Antibody that Selectively Depletes Intratumoral Treg Cells and Induces Antitumor Immune Responses
Treg gating strategy of CHS-114 clinical samples
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from CHS-114: An Afucosylated Anti-CCR8 Monoclonal Antibody that Selectively Depletes Intratumoral Treg Cells and Induces Antitumor Immune Responses
Targeting CCR8 Tregs in B16F10 tumors induces effector T cell proliferation and increases their expression of proinflammatory cytokines and chemokines
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from CHS-114: An Afucosylated Anti-CCR8 Monoclonal Antibody that Selectively Depletes Intratumoral Treg Cells and Induces Antitumor Immune Responses
Targeting CCR8 Tregs in B16F10 tumors induces effector T cell proliferation and increases their expression of proinflammatory cytokines and chemokines
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from CHS-114: An Afucosylated Anti-CCR8 Monoclonal Antibody that Selectively Depletes Intratumoral Treg Cells and Induces Antitumor Immune Responses
CHS-114 treatment results in antitumor activity in tumor bearing huCCR8 knock-in mice
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from CHS-114: An Afucosylated Anti-CCR8 Monoclonal Antibody that Selectively Depletes Intratumoral Treg Cells and Induces Antitumor Immune Responses
CHS-114 treatment results in antitumor activity in tumor bearing huCCR8 knock-in mice
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from CHS-114: An Afucosylated Anti-CCR8 Monoclonal Antibody that Selectively Depletes Intratumoral Treg Cells and Induces Antitumor Immune Responses
Correlation of CCR8 expression with Treg signature in multiple tumor types.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from CHS-114: An Afucosylated Anti-CCR8 Monoclonal Antibody that Selectively Depletes Intratumoral Treg Cells and Induces Antitumor Immune Responses
Correlation of CCR8 expression with Treg signature in multiple tumor types.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from CHS-114: An Afucosylated Anti-CCR8 Monoclonal Antibody that Selectively Depletes Intratumoral Treg Cells and Induces Antitumor Immune Responses
CHS-114 potently binds to human CCR8 and induces ADCC
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from CHS-114: An Afucosylated Anti-CCR8 Monoclonal Antibody that Selectively Depletes Intratumoral Treg Cells and Induces Antitumor Immune Responses
CHS-114 potently binds to human CCR8 and induces ADCC
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S7 from CHS-114: An Afucosylated Anti-CCR8 Monoclonal Antibody that Selectively Depletes Intratumoral Treg Cells and Induces Antitumor Immune Responses
CCR8+ Tregs are more abundant in PD-L1+ HNSCC, NSCLC, gastric cancer and cervical SCC but show similar abundance in HPV+ and HPV- HNSCC samples.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S7 from CHS-114: An Afucosylated Anti-CCR8 Monoclonal Antibody that Selectively Depletes Intratumoral Treg Cells and Induces Antitumor Immune Responses
CCR8+ Tregs are more abundant in PD-L1+ HNSCC, NSCLC, gastric cancer and cervical SCC but show similar abundance in HPV+ and HPV- HNSCC samples.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from CHS-114: An Afucosylated Anti-CCR8 Monoclonal Antibody that Selectively Depletes Intratumoral Treg Cells and Induces Antitumor Immune Responses
Anti-CCR8 monoclonal antibody treatment has no effect on Tregs- of spleen or draining lymph node (dLN).
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from CHS-114: An Afucosylated Anti-CCR8 Monoclonal Antibody that Selectively Depletes Intratumoral Treg Cells and Induces Antitumor Immune Responses
Anti-CCR8 monoclonal antibody treatment has no effect on Tregs- of spleen or draining lymph node (dLN).